TY - JOUR
T1 - Automated text-level semantic markers of Alzheimer's disease
AU - Sanz, Camila
AU - Carrillo, Facundo
AU - Slachevsky, Andrea
AU - Forno, Gonzalo
AU - Gorno Tempini, Maria Luisa
AU - Villagra, Roque
AU - Ibáñez, Agustín
AU - Tagliazucchi, Enzo
AU - García, Adolfo M.
N1 - Funding Information:
Andrea Slachevsky has received support from ANID/FONDAP/15150012, ANID/FONDEF/18I10113, ANID/Fondecyt/1191726, 1210176, and 1210195; and MULTI‐PARTNER CONSORTIUM TO EXPAND DEMENTIA RESEARCH IN LATIN AMERICA (ReDLat, supported by National Institutes of Health, National Institutes of Aging [R01 AG057234], Alzheimer's Association [SG‐20‐725707], Tau Consortium, and Global Brain Health Institute) and Alzheimer's Association GBHI ALZ UK‐20‐639295. In the past 36 months, Andrea Slachevsky has received grants from ANID/FONDAP/15150012, ANID/Fondecyt Regular/1191726, and the MULTI‐PARTNER CONSORTIUM TO EXPAND DEMENTIA RESEARCH IN LATIN AMERICA (ReDLat, supported by National Institutes of Health, National Institutes of Aging [R01 AG057234], Alzheimer's Association [SG‐20‐725707], Tau Consortium, and Global Brain Health Institute) and Alzheimer's Association GBHI ALZ UK‐20‐639295. In the past 36 months, Andrea Slachevsky has served as Board Director for the Global Brain Health Institute and BrainLat, Member of the Scientific Program Committee of the Alzheimer's Association International Congress AAIC, and Vice President of the non‐profit organization COPRAD (Corporacion Profesional de Alzheimer y Otras demencia). Facundo Carrillo has stocks of a company that makes EHR for mental health professionals (Sigmind: https://www.sigmind.net ). In the past 36 months, Facundo Carrillo had a fellowship with a travel grant. In the past 36 months, Gonzalo Forno has served as Associate Professor at Universidad de Los Andes, Santiago, Chile. In the past 36 months, Maria Luisa Gorno Tempini has been supported by grants from the National Institutes of Health (NINDS R01 NS050915, NIDCD K24 DC015544; NIA U01 AG052943). Roque Villagra has received support from ANID/FONDAP/15150012. In the past 36 months, Agustín Ibáñez has been partially supported by grants from CONICET; ANID/FONDECYT Regular (1170010); FONCYT‐PICT 2017‐1820; ANID/FONDAP/15150012; Takeda CW2680521; Sistema General de Regalías (BPIN2018000100059), Universidad del Valle (CI 5316) Alzheimer's Association GBHI ALZ UK‐20‐639295; and the MULTIPARTNER CONSORTIUM TO EXPAND DEMENTIA RESEARCH IN LATIN AMERICA (ReDLat, supported by National Institutes of Health, National Institutes of Aging [R01 AG057234], Alzheimer's Association [SG‐20‐725707], Rainwater Charitable foundation ‐ Tau Consortium, and Global Brain Health Institute). The contents of this publication are solely the responsibility of the authors and do not represent the official views of these Institutions. Adolfo García is an Atlantic Fellow at the Global Brain Health Institute (GBHI) and is supported with funding from GBHI, Alzheimer's Association, and Alzheimer's Society (GBHI ALZ UK‐22‐865742); CONICET; FONCYT‐PICT (grant number 2017‐1818); ANID, FONDECYT Regular (grant numbers 1210176 and 1210195); and Programa Interdisciplinario de Investigación Experimental en Comunicación y Cognición (PIIECC), Facultad de Humanidades. In the past 36 months, Adolfo García has received grants from the GBHI, the Alzheimer's Association, the Alzheimer's Society, and ANID (FONDECYT Regular 1210176). He has also served as advisory board member for the BrainLat Institute (Chile). No payments are involved in this appointment. In the past 36 months no author has received any royalties, licenses, consulting fees; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events, expert testimony; support for attending meetings and/or travel; equipment, materials, drugs, medical writing, gifts, or other services. In the past 36 months, no author has had any patents planned, issued, or pending; nor any financial or non‐financial interests. Camila Sanz, Roque Villagra, and Enzo Tagliazucchi have nothing to disclose. We express our deep gratitude to all participants as well as the patients' caregivers for contributing their valuable time to this study.
Publisher Copyright:
© 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.
PY - 2022
Y1 - 2022
N2 - Introduction: Automated speech analysis has emerged as a scalable, cost-effective tool to identify persons with Alzheimer's disease dementia (ADD). Yet, most research is undermined by low interpretability and specificity. Methods: Combining statistical and machine learning analyses of natural speech data, we aimed to discriminate ADD patients from healthy controls (HCs) based on automated measures of domains typically affected in ADD: semantic granularity (coarseness of concepts) and ongoing semantic variability (conceptual closeness of successive words). To test for specificity, we replicated the analyses on Parkinson's disease (PD) patients. Results: Relative to controls, ADD (but not PD) patients exhibited significant differences in both measures. Also, these features robustly discriminated between ADD patients and HC, while yielding near-chance classification between PD patients and HCs. Discussion: Automated discourse-level semantic analyses can reveal objective, interpretable, and specific markers of ADD, bridging well-established neuropsychological targets with digital assessment tools.
AB - Introduction: Automated speech analysis has emerged as a scalable, cost-effective tool to identify persons with Alzheimer's disease dementia (ADD). Yet, most research is undermined by low interpretability and specificity. Methods: Combining statistical and machine learning analyses of natural speech data, we aimed to discriminate ADD patients from healthy controls (HCs) based on automated measures of domains typically affected in ADD: semantic granularity (coarseness of concepts) and ongoing semantic variability (conceptual closeness of successive words). To test for specificity, we replicated the analyses on Parkinson's disease (PD) patients. Results: Relative to controls, ADD (but not PD) patients exhibited significant differences in both measures. Also, these features robustly discriminated between ADD patients and HC, while yielding near-chance classification between PD patients and HCs. Discussion: Automated discourse-level semantic analyses can reveal objective, interpretable, and specific markers of ADD, bridging well-established neuropsychological targets with digital assessment tools.
KW - Alzheimer's disease dementia
KW - Parkinson's disease
KW - automated speech analysis
KW - semantic granularity
KW - semantic variability
UR - http://www.scopus.com/inward/record.url?scp=85131522933&partnerID=8YFLogxK
U2 - 10.1002/dad2.12276
DO - 10.1002/dad2.12276
M3 - Article
AN - SCOPUS:85131522933
SN - 2352-8729
VL - 14
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
IS - 1
M1 - e12276
ER -